Skip to main content
. 2021 May 18;42(27):2643–2654. doi: 10.1093/eurheartj/ehab280

graphic file with name ehab280f7.jpg

Summary of pooled estimates for key clinical endpoints at latest follow-up. Results from a random-effects meta-analysis of 16 trials in which 20 701 patients were randomized to ultrathin-strut drug-eluting stents (≤70 µm strut thickness) compared with conventional 2nd-generation thin-strut drug-eluting stents. The weighted mean follow-up duration was 2.5 years.